Cargando…

HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trial

This prospective study evaluated whether baseline cholesterol efflux is associated with future development of type 2 diabetes (T2DM) in cardiovascular patients. We measured cholesterol efflux in all CORDIOPREV study (NCT00924937) participants free of T2DM at baseline (n = 462) and assessed its relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blanco-Rojo, Ruth, Perez-Martinez, Pablo, Lopez-Moreno, Javier, Martinez-Botas, Javier, Delgado-Lista, Javier, van-Ommen, Ben, Yubero-Serrano, Elena, Camargo, Antonio, Ordovas, Jose M., Perez-Jimenez, Francisco, Gomez-Coronado, Diego, Lopez-Miranda, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624929/ https://www.ncbi.nlm.nih.gov/pubmed/28970513 http://dx.doi.org/10.1038/s41598-017-12678-9

Ejemplares similares

Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
por: Yubero-Serrano, Elena M., et al.
Publicado: (2021)

Correction to: Association between cholesterol efflux capacity and peripheral artery disease in coronary heart disease patients with and without type 2 diabetes: from the CORDIOPREV study
por: Yubero-Serrano, Elena M., et al.
Publicado: (2021)

A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study
por: Jiménez-Lucena, Rosa, et al.
Publicado: (2018)

Mediterranean diet and endothelial function in patients with coronary heart disease: An analysis of the CORDIOPREV randomized controlled trial
por: Yubero-Serrano, Elena M., et al.
Publicado: (2020)

Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary Heart Disease Patients from the CORDIOPREV Study
por: Jiménez-Lucena, Rosa, et al.
Publicado: (2018)

An altered microbiota pattern precedes Type 2 diabetes mellitus development: From the CORDIOPREV study
por: Vals-Delgado, Cristina, et al.
Publicado: (2021)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Hypertriglyceridemia Influences the Degree of Postprandial Lipemic Response in Patients with Metabolic Syndrome and Coronary Artery Disease: From the Cordioprev Study
por: Alcala-Diaz, Juan F., et al.
Publicado: (2014)

Influence of Obesity and Metabolic Disease on Carotid Atherosclerosis in Patients with Coronary Artery Disease (CordioPrev Study)
por: Talavera-Garcia, Eva, et al.
Publicado: (2016)

Correction: Influence of Obesity and Metabolic Disease on Carotid Atherosclerosis in Patients with Coronary Artery Disease (CordioPrev Study)
por: Talavera-Garcia, Eva, et al.
Publicado: (2016)

A microbiota‐based predictive model for type 2 diabetes remission induced by dietary intervention: From the CORDIOPREV study
por: Vals‐Delgado, Cristina, et al.
Publicado: (2021)

Diet and SIRT1 Genotype Interact to Modulate Aging-Related Processes in Patients with Coronary Heart Disease: From the CORDIOPREV Study
por: Hidalgo-Moyano, Cristina, et al.
Publicado: (2022)

A set of miRNAs predicts T2DM remission in patients with coronary heart disease: from the CORDIOPREV study
por: Rangel-Zuñiga, Oriol Alberto, et al.
Publicado: (2020)

Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
por: Daniil, Georgios, et al.
Publicado: (2013)

Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux
por: Nilsson, Oktawia, et al.
Publicado: (2020)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

Metabolomics analysis of type 2 diabetes remission identifies 12 metabolites with predictive capacity: a CORDIOPREV clinical trial study
por: Mora-Ortiz, Marina, et al.
Publicado: (2022)

Correction: Effect of apoA-I Mutations in the Capacity of Reconstituted HDL to Promote ABCG1-Mediated Cholesterol Efflux
Publicado: (2014)

Changes in quantity plant-based protein intake on type 2 diabetes remission in coronary heart disease patients: from the CORDIOPREV study
por: Gutierrez-Mariscal, Francisco M., et al.
Publicado: (2023)

Long-term effect of a dietary intervention with two-healthy dietary approaches on food intake and nutrient density in coronary patients: results from the CORDIOPREV trial
por: Cano-Ibáñez, Naomi, et al.
Publicado: (2022)

Correction to: Long‑term effect of a dietary intervention with two‑healthy dietary approaches on food intake and nutrient density in coronary patients: results from the CORDIOPREV trial
por: Cano-Ibáñez, Naomi, et al.
Publicado: (2022)

Changes in Splicing Machinery Components Influence, Precede, and Early Predict the Development of Type 2 Diabetes: From the CORDIOPREV Study
por: Gahete, Manuel D., et al.
Publicado: (2018)

Age-dependent effect of metabolic phenotypes on carotid atherosclerotic disease in coronary heart disease patients (CORDIOPREV study)
por: Gutierrez-Mariscal, Francisco M., et al.
Publicado: (2020)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

Plasma lipidic fingerprint associated with type 2 diabetes in patients with coronary heart disease: CORDIOPREV study
por: Villasanta-Gonzalez, Alejandro, et al.
Publicado: (2023)

A plasma fatty acid profile associated to type 2 diabetes development: from the CORDIOPREV study
por: Villasanta-Gonzalez, Alejandro, et al.
Publicado: (2021)

Evolution of Metabolic Phenotypes of Obesity in Coronary Patients after 5 Years of Dietary Intervention: From the CORDIOPREV Study
por: Martin-Piedra, Laura, et al.
Publicado: (2021)

Quality and Quantity of Protein Intake Influence Incidence of Type 2 Diabetes Mellitus in Coronary Heart Disease Patients: From the CORDIOPREV Study
por: de la Cruz-Ares, Silvia, et al.
Publicado: (2021)

Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome
por: Ng, Theodore W. K., et al.
Publicado: (2009)

Hepatic insulin resistance both in prediabetic and diabetic patients determines postprandial lipoprotein metabolism: from the CORDIOPREV study
por: Leon-Acuña, A., et al.
Publicado: (2016)

ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity
por: Luo, Mengdie, et al.
Publicado: (2017)

Bariatric Surgery Improves HDL Function Examined by ApoA1 Exchange Rate and Cholesterol Efflux Capacity in Patients with Obesity and Type 2 Diabetes
por: Lorkowski, Shuhui Wang, et al.
Publicado: (2020)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator
por: Kido, Toshimi, et al.
Publicado: (2017)

Antibodies Against the C-Terminus of ApoA-1 Are Inversely Associated with Cholesterol Efflux Capacity and HDL Metabolism in Subjects with and without Type 2 Diabetes Mellitus
por: Dullaart, Robin P. F., et al.
Publicado: (2019)

Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle
por: Dalla-Riva, Jonathan, et al.
Publicado: (2013)

Endothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Study
por: de la Cruz-Ares, Silvia, et al.
Publicado: (2020)

Incubation of MDCO-216 (ApoA-IMilano/POPC) with Human Serum Potentiates ABCA1-Mediated Cholesterol Efflux Capacity, Generates New Prebeta-1 HDL, and Causes an Increase in HDL Size
por: Kempen, Herman J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hcunqlm2ntumpt9auqucs3nnjm